X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with FDC LTD. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs FDC LTD. - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES FDC LTD. ALKEM LABORATORIES/
FDC LTD.
 
P/E (TTM) x - 22.2 - View Chart
P/BV x 7.1 5.0 142.2% View Chart
Dividend Yield % 0.6 0.9 64.4%  

Financials

 ALKEM LABORATORIES   FDC LTD.
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
FDC LTD.
Mar-14
ALKEM LABORATORIES/
FDC LTD.
5-Yr Chart
Click to enlarge
High Rs1,589144 1,107.3%   
Low Rs1,23279 1,559.5%   
Sales per share (Unadj.) Rs417.547.6 877.7%  
Earnings per share (Unadj.) Rs56.37.6 739.8%  
Cash flow per share (Unadj.) Rs64.79.0 718.2%  
Dividends per share (Unadj.) Rs12.702.25 564.4%  
Dividend yield (eoy) %0.92.0 44.5%  
Book value per share (Unadj.) Rs292.947.5 616.3%  
Shares outstanding (eoy) m119.57177.83 67.2%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x3.42.3 144.5%   
Avg P/E ratio x25.114.6 171.4%  
P/CF ratio (eoy) x21.812.3 176.5%  
Price / Book Value ratio x4.82.3 205.7%  
Dividend payout %22.629.6 76.3%   
Avg Mkt Cap Rs m168,65319,784 852.5%   
No. of employees `000NANA-   
Total wages/salary Rs m9,1711,221 751.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m49,9158,459 590.1%  
Other income Rs m1,645394 418.0%   
Total revenues Rs m51,5618,852 582.5%   
Gross profit Rs m8,4822,070 409.7%  
Depreciation Rs m1,006249 403.8%   
Interest Rs m67131 2,162.5%   
Profit before tax Rs m8,4512,184 387.0%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m0-225 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,606606 265.2%   
Profit after tax Rs m6,7311,353 497.4%  
Gross profit margin %17.024.5 69.4%  
Effective tax rate %19.027.7 68.5%   
Net profit margin %13.516.0 84.3%  
BALANCE SHEET DATA
Current assets Rs m27,0624,355 621.3%   
Current liabilities Rs m15,3241,792 855.2%   
Net working cap to sales %23.530.3 77.6%  
Current ratio x1.82.4 72.7%  
Inventory Days Days6744 149.6%  
Debtors Days Days4125 167.4%  
Net fixed assets Rs m12,6103,025 416.8%   
Share capital Rs m239179 133.9%   
"Free" reserves Rs m34,4908,243 418.4%   
Net worth Rs m35,0278,453 414.4%   
Long term debt Rs m1,21211 11,323.4%   
Total assets Rs m54,38710,557 515.2%  
Interest coverage x13.671.4 19.0%   
Debt to equity ratio x00 2,732.7%  
Sales to assets ratio x0.90.8 114.5%   
Return on assets %13.613.1 103.8%  
Return on equity %19.216.0 120.0%  
Return on capital %24.923.5 105.7%  
Exports to sales %12.913.3 97.3%   
Imports to sales %3.13.3 92.3%   
Exports (fob) Rs m6,4611,126 574.0%   
Imports (cif) Rs m1,540283 544.7%   
Fx inflow Rs m6,5631,146 572.7%   
Fx outflow Rs m3,012355 847.6%   
Net fx Rs m3,552791 449.1%   
CASH FLOW
From Operations Rs m7,2591,485 488.8%  
From Investments Rs m1,864-620 -300.9%  
From Financial Activity Rs m-9,273-753 1,232.3%  
Net Cashflow Rs m-150113 -133.0%  

Share Holding

Indian Promoters % 66.9 68.9 97.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 4.7 704.3%  
FIIs % 0.0 7.5 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 19.0 -  
Shareholders   68,381 23,730 288.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   SUN PHARMA  DR. REDDYS LAB  GSK PHARMA  UNICHEM LAB  MERCK LTD  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

FDC LTD. Announces Quarterly Results (1QFY19); Net Profit Up 74.5% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, FDC LTD. has posted a net profit of Rs 511 m (up 74.5% YoY). Sales on the other hand came in at Rs 3 bn (up 16.7% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

FDC LTD. Announces Quarterly Results (4QFY18); Net Profit Down 35.8% (Quarterly Result Update)

Jul 20, 2018 | Updated on Jul 20, 2018

For the quarter ended March 2018, FDC LTD. has posted a net profit of Rs 315 m (down 35.8% YoY). Sales on the other hand came in at Rs 3 bn (up 5.9% YoY). Read on for a complete analysis of FDC LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Sep 21, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 5-YR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS